Bloodstream infections in cancer patients with febrile neutropenia

被引:74
|
作者
Feld, Ronald [1 ]
机构
[1] Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Dept Med,Div Hematol & Med Oncol, Toronto, ON M5G 2M9, Canada
关键词
Bacteraemia; Febrile neutropenia; Predictive laboratory markers;
D O I
10.1016/j.ijantimicag.2008.06.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Bloodstream infections (bacteraemia) account for approximately 25-30% of febrile episodes in patients with febrile neutropenia (FN). In developed countries, Gram-positive pathogens predominate. Mortality is higher in Gram-negative bacteraemia. A recent study involving 2142 patients with FN was reviewed, including 168 patients with Gram-negative bacteraemia (mortality 18%), 283 patients with Gram-positive bacteraemia (mortality 5%) and 48 patients with polymicrobial bacteraemia (mortality 13%). Among patients who received prophylactic antibiotics, Gram-positive bacteraemia was far more common than Gram-negative bacteraemia (75% vs. 25%), compared with approximately 50% of each in patients without prophylactic antibiotics. Patients with a Multinational Association for Supportive Care in Cancer (MASCC) score < 15 had a 36% mortality compared with 3% if the MASCC score was > 21. The MASCC score may help risk strati. cation of patients with FN and bacteraemia, although these data require confirmation. In two series of patients from developing countries (Lebanon and Malaysia), Gram-negative bacteraemia was more common and mortality was higher. In developing countries, Gram-negative bacteraemia may be more frequent due to less use of prophylactic antibiotics and central lines. Laboratory markers may have predictive and prognostic value for bacteraemia in patients at the onset of FN, including mannose-binding lectin, interleukin (IL)-6, IL-8 and procalcitonin, but further studies are required before they can be recommended. New therapies are required to lower the mortality in patients with FN with a high risk for bacteraemia. (c) 2008 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:S30 / S33
页数:4
相关论文
共 50 条
  • [31] Direct costs of febrile neutropenia in cancer patients
    van Gogh, Evelien
    Specenier, Pol
    Strens, Danielle
    ACTA CLINICA BELGICA, 2017, 72 : 13 - 13
  • [32] Impact of fluoroquinolone prophylaxis on documented infections in patients with febrile neutropenia
    Przybylski, Daniel J.
    Reeves, David J.
    INFECTIOUS DISEASES, 2018, 50 (05) : 395 - 398
  • [33] Infections in patients with febrile neutropenia: Epidemiology, microbiology, and risk stratification
    Viscoli, C
    Varnier, O
    Machetti, M
    CLINICAL INFECTIOUS DISEASES, 2005, 40 : S240 - S245
  • [34] EVALUATION OF BLOODSTREAM INFECTIONS DURING CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA IN PATIENTS WITH MALIGNANT HEMATOLOGICAL DISEASES: SINGLE CENTER EXPERIENCE
    Piukovics, Klara
    Terhes, Gabriella
    Lazar, Andrea
    Timar, Flora
    Borbenyi, Zita
    Urban, Edit
    EUROPEAN JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY, 2015, 5 (03): : 199 - 204
  • [35] Clinical outcome in children with cancer, fever and neutropenia, with polymicrobial bloodstream infections
    Santolaya, M.
    Ibanez, C.
    Torres, J.
    de la Maza, V.
    Rivera, S.
    Valenzuela, R.
    Simian, E.
    Contardo, V.
    Paya, E.
    Alvarez, A.
    Martinez, D.
    Claverie, X.
    SWISS MEDICAL WEEKLY, 2022, 152 : 24S - 24S
  • [36] CATHETER RELATED BLOODSTREAM INFECTIONS IN FEBRILE NONNEUTROPENIC PEDIATRIC ONCOLOGY PATIENTS
    Kelly, Michael J.
    Panken, Tali M.
    Schwartz, Cindy L.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (06) : 717 - 718
  • [37] Association between inappropriate empirical antimicrobial therapy and mortality in gram-negative bloodstream infections in patients with febrile neutropenia and hematological malignancy
    Riano, Ariel Fernando Florez
    Castro, Oscar Julian Rojas
    Ospina, Sigifredo
    Ramirez-Sanchez, Isabel Cristina
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2025, 31 (02)
  • [38] Management of infection and febrile neutropenia in patients with solid cancer
    J. A. Virizuela
    J. Carratalà
    J. M. Aguado
    D. Vicente
    M. Salavert
    M. Ruiz
    I. Ruiz
    F. Marco
    M. Lizasoain
    P. Jiménez-Fonseca
    C. Gudiol
    J. Cassinello
    A. Carmona-Bayonas
    M. Aguilar
    J. J. Cruz
    Clinical and Translational Oncology, 2016, 18 : 557 - 570
  • [39] Time to antibiotics and outcomes in cancer patients with febrile neutropenia
    Perron, Thomas
    Emara, Mohamed
    Ahmed, Shahid
    BMC HEALTH SERVICES RESEARCH, 2014, 14
  • [40] Risk of mortality in patients with cancer experiencing febrile neutropenia
    Barron, R.
    Michels, S. L.
    Reynolds, M. W.
    Tomic, K.
    Yu, J.
    Lyman, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)